Goodwin Investment Advisory’s Axsome Therapeutics AXSM Stock Holding History

Goodwin Investment Advisory’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$717K	Hold	4,241	–	–	0.85%	14
2025 Q4	$775K	Hold	4,241	–	–	0.85%	14
2025 Q3	$515K	Hold	4,241	–	–	0.55%	15
2025 Q2	$443K	Hold	4,241	–	–	0.51%	16
2025 Q1	$495K	Hold	4,241	–	–	0.77%	15
2024 Q4	$359K	Hold	4,241	–	–	0.19%	30
2024 Q3	$381K	Hold	4,241	–	–	0.17%	25
2024 Q2	$341K	Hold	4,241	–	–	0.16%	26
2024 Q1	$338K	Buy	+4,241	New	+$356K	0.16%	26

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goodwin Investment Advisory's AXSM Position: Q1 2026 in Review

Goodwin Investment Advisory held its Axsome Therapeutics (AXSM) position steady in Q1 2026 at 4,241 shares worth $717K. The position accounts for 0.85% of the portfolio, ranked #14.

Goodwin Investment Advisory first reported a position in AXSM in Q1 2024 and has held it in 9 quarters since. The position peaked at $775K in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

Goodwin Investment Advisory held 4,241 shares of Axsome Therapeutics worth $717K as of Q1 2026.
Goodwin Investment Advisory left its Axsome Therapeutics share count unchanged in Q1 2026.
Axsome Therapeutics made up 0.85% of Goodwin Investment Advisory's portfolio in Q1 2026, its #14 holding.
Goodwin Investment Advisory first reported a position in Axsome Therapeutics in Q1 2024 and has held it in 9 quarters since.
Goodwin Investment Advisory's Axsome Therapeutics position peaked at $775K in Q4 2025.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Goodwin Investment Advisory's 13F filing for Q1 2026, filed 13 May 2026.